raloxifene hydrochloride has been researched along with Cancer of the Uterus in 46 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (15.22) | 18.2507 |
2000's | 32 (69.57) | 29.6817 |
2010's | 6 (13.04) | 24.3611 |
2020's | 1 (2.17) | 2.80 |
Authors | Studies |
---|---|
Bryant, HU; Cohen, IR; Dally, RD; Dodge, JA; Fong, KC; Frank, SA; Geiser, AG; Hinklin, R; Hummel, CW; Jones, SA; Lewis, G; McCann, DJ; Rudmann, DG; Shepherd, TA; Tian, H; Wallace, OB; Wang, M; Wang, Y | 1 |
Shieh, Y; Tice, JA | 1 |
Brito, LG; Candido Dos Reis, FJ; Ferriani, RA; Martins, WP; Moroni, RM; Nastri, CO; Vieira, CS | 1 |
Neves-E-Castro, M | 1 |
Castle, PE | 1 |
Lethaby, A; Vollenhoven, B | 1 |
Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Runowicz, CD; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
Creasman, WT | 1 |
Chen, XY; Deng, L; Wu, T; Xie, L; Yang, J | 1 |
Lombardi, G; Morelli, M; Nappi, C; Orio, F; Palomba, S; Panici, PL; Pellicano, M; Russo, T; Zullo, F; Zupi, E | 1 |
Colao, A; Lombardi, G; Mastrantonio, P; Morelli, M; Nappi, C; Orio, F; Palomba, S; Pellicano, M; Russo, T; Zullo, F | 1 |
Colao, A; Lombardi, G; Nappi, C; Orio, F; Palomba, S; Panici, PL; Russo, T; Tauchmanovà, L; Zullo, F; Zupi, E | 1 |
Touraine, P | 1 |
Amant, F; Joubert, A; Lindeque, BG; Lottering, ML; Thaver, V; Vergote, I | 1 |
Smith, RE | 1 |
Crans, G; Eppel, W; Jirecek, S; Lee, A; Pavo, I; Wenzl, R | 1 |
Colao, A; Lombardi, G; Mastrantonio, P; Nappi, C; Orio, F; Palomba, S; Russo, T; Sammartino, A; Sbano, FM; Zullo, F | 1 |
Cascella, T; Doldo, P; Falbo, A; Lombardi, G; Mastrantonio, P; Nappi, C; Orio, F; Palomba, S; Russo, T; Zullo, F | 1 |
Lombardi, G; Orio, F; Palomba, S; Zullo, F | 1 |
Christopoulos, S; Rivera, JA; Small, D; Trifiro, M | 1 |
Amati, A; Falbo, A; Orio, F; Palomba, S; Russo, T; Zullo, F | 1 |
de Los Angeles, MM; Goldberg, GL; Goldman, NA; Jones, JG | 1 |
Cimini, V; Falbo, A; Lombardi, G; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F | 1 |
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
Vastag, B | 1 |
Baytur, YB; Cilaker, S; Koyuncu, FM; Kurtul, O; Lacin, S; Oruc, S; Ozbilgin, K | 1 |
Benetti-Pinto, CL; De Angelo-Andrade, LA; Petta, CA; Soares, PM | 1 |
Asselin, E; Bélanger, G; Boucher, V; Déry, MC; Leblanc, K; Parent, S; Sexton, E | 1 |
Chen, W; Liu, J; Maruo, T; Matsuo, H; Wang, J; Xu, Q | 1 |
Lingxia, X; Taixiang, W; Xiaoyan, C | 1 |
Labrie, F | 1 |
Lethaby, AE; Vollenhoven, BJ | 1 |
Chen, X; Wu, T; Xie, L | 1 |
Fuchs-Young, R; Hale, L; Howe, S; Miles, R; Walker, C | 1 |
Nelson, NJ | 1 |
Jordan, VC | 1 |
Fuchs-Young, R; Nicosia, SV; O'Brien, WF; Porter, GW; Porter, KB; Spellacy, WN; Tsibris, JC | 1 |
Eppes, PG; Wilson, CT; Wozniak, TF | 1 |
Affinito, P; Di Carlo, C; Nappi, C; Palomba, S; Sammartino, A; Zullo, F | 1 |
Pfeilschifter, J | 1 |
Ang, WC; Farrell, E; Vollenhoven, B | 1 |
Katzenellenbogen, BS; Katzenellenbogen, JA | 1 |
Gottardis, MM; Jordan, VC; Satyaswaroop, PG | 1 |
15 review(s) available for raloxifene hydrochloride and Cancer of the Uterus
Article | Year |
---|---|
Medications for Primary Prevention of Breast Cancer.
Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Venous Thromboembolism | 2020 |
Add-back therapy with GnRH analogues for uterine fibroids.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estriol; Female; Gonadotropin-Releasing Hormone; Humans; Isoflavones; Leiomyoma; Medroxyprogesterone; Norpregnenes; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Hemorrhage; Uterine Neoplasms | 2015 |
Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
Topics: Estrogen Replacement Therapy; Estrogens; Female; Humans; Norpregnenes; Ovarian Neoplasms; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms | 2008 |
Fibroids (uterine myomatosis, leiomyomas).
Topics: Humans; Leiomyoma; Menopause; Pain; Premenopause; Progestins; Raloxifene Hydrochloride; Regression Analysis; Uterine Neoplasms | 2011 |
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
Topics: Adult; Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms; Young Adult | 2012 |
[SERMs and uterus].
Topics: Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Uterus | 2003 |
A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Risk; Sarcoma; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2003 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropathies; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasms; Nitriles; Radiography, Thoracic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; Uterine Neoplasms | 2004 |
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
Topics: Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2007 |
Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2007 |
An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Estrogen Antagonists; Evidence-Based Medicine; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Norpregnenes; Premenopause; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2008 |
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
Topics: Female; Humans; Leiomyoma; Leuprolide; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2007 |
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms | 1998 |
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms | 2001 |
Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
Topics: Animals; Disease Models, Animal; Estrogen Replacement Therapy; Female; Humans; Leiomyoma; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2001 |
12 trial(s) available for raloxifene hydrochloride and Cancer of the Uterus
Article | Year |
---|---|
Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study.
Topics: Adult; Estrogen Antagonists; Female; Humans; Leiomyoma; Pilot Projects; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Single-Blind Method; Treatment Outcome; Uterine Neoplasms | 2002 |
Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Topics: Adult; Body Mass Index; Bone and Bones; Bone Density; Calcium; Delayed-Action Preparations; Female; Femur; Humans; Leiomyoma; Leuprolide; Lumbar Vertebrae; Middle Aged; Osteoporosis; Phosphorus; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2002 |
Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
Topics: Delayed-Action Preparations; Female; Hot Flashes; Humans; Leiomyoma; Leuprolide; Menorrhagia; Pain; Patient Dropouts; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Neoplasms | 2002 |
Raloxifene prevents the growth of uterine leiomyomas in premenopausal women.
Topics: Adult; Estradiol; Female; Follicle Stimulating Hormone; Humans; Leiomyoma; Middle Aged; Premenopause; Prolactin; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Testosterone; Thyrotropin; Thyroxine; Ultrasonography; Uterine Neoplasms | 2004 |
Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene.
Topics: Adult; Blood Glucose; Body Constitution; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Female; Folic Acid; Homeostasis; Homocysteine; Humans; Insulin; Insulin Resistance; Leiomyoma; Leuprolide; Lipids; Middle Aged; Placebos; Premenopause; Raloxifene Hydrochloride; Triglycerides; Uterine Neoplasms; Vitamin B 12 | 2004 |
Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Topics: Antineoplastic Agents, Hormonal; Blood Glucose; Bone Density; Bone Remodeling; Delayed-Action Preparations; Drug Therapy, Combination; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Leuprolide; Lipids; Longitudinal Studies; Middle Aged; Patient Dropouts; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Treatment Outcome; Uterine Neoplasms; Vasomotor System | 2004 |
Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life.
Topics: Adult; Affect; Analysis of Variance; Cognition; Estrogen Antagonists; Female; Gonadotropin-Releasing Hormone; Humans; Italy; Leiomyoma; Patient Selection; Placebos; Premenopause; Quality of Life; Raloxifene Hydrochloride; Single-Blind Method; Socioeconomic Factors; Uterine Neoplasms | 2004 |
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.
Topics: Apoptosis; Cell Proliferation; Double-Blind Method; Female; Growth Inhibitors; Humans; Leiomyoma; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Uterine Neoplasms | 2005 |
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms | 2006 |
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Topics: Adult; Antineoplastic Agents, Hormonal; Female; Genes, bcl-2; Goserelin; Humans; Leiomyoma; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tumor Suppressor Protein p53; Uterine Neoplasms | 2007 |
Drugs can reduce the incidence of breast cancer: now what?
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 1999 |
Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women.
Topics: Double-Blind Method; Estrogen Antagonists; Female; Humans; Leiomyoma; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Uterine Neoplasms; Uterus | 2001 |
19 other study(ies) available for raloxifene hydrochloride and Cancer of the Uterus
Article | Year |
---|---|
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Leiomyoma; Mammary Glands, Animal; Models, Molecular; Naphthalenes; Organ Size; Ovary; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterine Neoplasms; Uterus | 2005 |
Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms | 2011 |
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Hyperplasia; Estrogen Antagonists; Female; Follow-Up Studies; Hot Flashes; Humans; Incidence; Leiomyoma; Middle Aged; Ovarian Cysts; Polyps; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms; Vaginal Discharge | 2011 |
What is the significance of gynecologic symptoms in the participants in the NSABP study?
Topics: Breast Neoplasms; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms | 2011 |
ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).
Topics: Adult; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 2002 |
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Topics: Antineoplastic Agents, Hormonal; Carcinosarcoma; Cell Cycle; Cell Division; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Progesterone; Raloxifene Hydrochloride; Tamoxifen; Triptorelin Pamoate; Uterine Neoplasms | 2003 |
Does raloxifene inhibit the growth of uterine fibroids?
Topics: Cell Division; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2004 |
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
Topics: Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Osteoporosis, Postmenopausal; Ovariectomy; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms | 2005 |
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms | 2006 |
Pulmonary benign metastasizing leiomyoma: a report of 2 cases with different outcomes.
Topics: Adult; Estrogen Antagonists; Female; Humans; Leiomyomatosis; Lung; Lung Neoplasms; Middle Aged; Myometrium; Ovariectomy; Raloxifene Hydrochloride; Treatment Outcome; Uterine Neoplasms | 2006 |
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Topics: Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Prohibitins; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Uterine Neoplasms | 2007 |
Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Topics: Adult; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Female; Humans; In Situ Nick-End Labeling; Leiomyoma; Middle Aged; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured; Uterine Neoplasms | 2007 |
Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Topics: Animals; Cell Division; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Leiomyoma; Phenotype; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Neoplasms | 1996 |
Anti-estrogens come of age: a pioneer looks back.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms | 1998 |
Effects of raloxifene in a guinea pig model for leiomyomas.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Guinea Pigs; Leiomyoma; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Ultrasonography; Uterine Neoplasms | 1998 |
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms | 2000 |
Raloxifene: new preparation. Not better than oestrogen.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms | 1999 |
Biomedicine. Defining the "S" in SERMs.
Topics: Breast; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Estradiol; Estrogen Replacement Therapy; Female; Histone Acetyltransferases; Humans; Ligands; Macromolecular Substances; Nuclear Receptor Coactivator 1; Organ Specificity; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Uterine Neoplasms; Uterus | 2002 |
Tamoxifen-stimulated growth of human endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clomiphene; Enclomiphene; Endometrium; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Mice, Inbred BALB C; Nafoxidine; Neoplasm Transplantation; Piperidines; Polyunsaturated Alkamides; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms | 1991 |